RGD Reference Report - [Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma]. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

[Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma].

Authors: Wang, Yuan-Yuan  Zhou, Chen-Jie  Li, Jing  Zhou, Ling  Li, Ming-Song  Xiao, Bing 
Citation: Wang YY, etal., Nan Fang Yi Ke Da Xue Xue Bao. 2017 Aug 20;37(8):1060-1065. doi: 10.3969/j.issn.1673-4254.2017.08.10.
RGD ID: 243065135
Pubmed: PMID:28801286   (View Abstract at PubMed)
PMCID: PMC6765739   (View Article at PubMed Central)
DOI: DOI:10.3969/j.issn.1673-4254.2017.08.10   (Journal Full-text)


OBJECTIVE: To explore the clinical value of detecting serum glypican-3 in the diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma (PHC).
METHODS: Using sandwich ELISA, we detected serum glypican-3 levels in 60 patients with PHC, 60 with metastatic liver cancer, 50 with liver cirrhosis, 50 with chronic viral hepatitis, 20 with hepatic cyst, 20 with fatty liver, 20 with hepatic hemangioma and 20 with drug-induced hepatitis as well as in 40 healthy subjects (control). We also analyzed the changes in serum levels of glypican-3 and alpha fetoprotein (AFP) in PHC patients after treatment.
RESULTS: PHC patients had significantly higher serum levels of glypican-3 than patients with other liver diseases and the control subjects (P<0.05). The levels of serum glypican-3 were significantly higher in patients with metastatic liver cancer, liver cirrhosis and viral hepatitis than in those with other benign liver diseases and the control subjects (P<0.05). Glypican-3 level was not associated with AFP level or liver function in PHC patients, in whom the positivity rates for glypican-3 and AFP were 65% and 56.7%, respectively. The detection rate of PHC increased to 85% by a combined detection of AFP and glypican-3. In the 23 PHC patients who responded positively to treatments, serum glypican-3 level showed a steady decline compared with that in 15 patients before treatment, while serum AFP level showed a similar decrease only in 10 patients.
CONCLUSION: Combined detection of glypican-3 and AFP is expected to improve the early diagnosis rate of PHC. The different thresholds of serum glypican-3 may play a role in the differential diagnosis of PHC and other various liver diseases. Glypican-3 may serve as a better marker than AFP with a high specificity and sensitivity for evaluating the therapeutic effect in PHC patients.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
GPC3Humanhepatocellular carcinoma  IEP protein:increased expression:blood serum (human)RGD 
Gpc3Rathepatocellular carcinoma  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
Gpc3Mousehepatocellular carcinoma  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
GPC3HumanHuman Viral Hepatitis  IEP protein:increased expression:blood serum (human)RGD 
Gpc3RatHuman Viral Hepatitis  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
Gpc3MouseHuman Viral Hepatitis  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
GPC3Humanliver cirrhosis  IEP protein:increased expression:blood serum (human)RGD 
Gpc3Ratliver cirrhosis  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
Gpc3Mouseliver cirrhosis  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
GPC3HumanLiver Metastasis  IEP protein:increased expression:blood serum (human)RGD 
Gpc3RatLiver Metastasis  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 
Gpc3MouseLiver Metastasis  ISOGPC3 (Homo sapiens)protein:increased expression:blood serum (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Gpc3  (glypican 3)

Genes (Mus musculus)
Gpc3  (glypican 3)

Genes (Homo sapiens)
GPC3  (glypican 3)


Additional Information